BioCentury
ARTICLE | Company News

Hyperion, Valeant Pharmaceuticals deal

June 10, 2013 7:00 AM UTC

Hyperion completed the acquisition of worldwide rights to Buphenyl sodium phenylbutyrate from Valeant's Ucyclyd Pharma Inc. subsidiary. The exercise price was $19 million. The subsidiary exercised its...